The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies
Abstract
The major impediment to the development of murine monoclonal antibodies (mAbs) for therapy in humans has been the difficulty in reducing their potential immunogenicity. XenoMouse¿trade mark omitted¿ mice obviate this problem while retaining the relative ease of generating mAbs from a mouse. XenoMouse strains include germline-configured, megabase-sized YACs carrying portions of the human IgH and Igkappa loci, including the majority of the variable region repertoire, the genes for Cmicro, Cdelta and either Cgamma1, Cgamma2, or Cgamma4, as well as the cis elements required for their function. The IgH and Igkappa transgenes were bred onto a genetic background deficient in production of murine immunoglobulin. The large and complex human variable region repertoire encoded on the Ig transgenes in XenoMouse strains support the development of large peripheral B cell compartments and the generation of a diverse primary immune repertoire similar to that from adult humans. Immunization of XenoMouse mice with human antigens routinely results in a robust secondary immune response, which can ultimately be captured as a large panel of antigen-specific fully human IgGkappa mAbs of sub-nanomolar affinities. Monoclonal antibodies from XenoMouse animals have been shown to have therapeutic potential both in vitro and in vivo, and appear to have the pharmacokinetics of normal human antibodies based on human clinical trials. The utility of XenoMouse strains for the generation of large panels of high-affinity, fully human mAbs can be made available to researchers in the academic and private sectors, and should accelerate the development and application of mAbs as therapeutics for human disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These mice were immunized with human RANKL, leading to an immune response that resulted in antigen-specific fully human IgGs that bind and inhibit RANKL (433).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [433]
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 945
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Bijl, J. A., & Woody, J. N. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90632-7 · Cited by 640
Kahan, B. D., Rajagopalan, P. R., & Hall, M. (1999) · Transplantation · doi:10.1097/00007890-199901270-00016 · Cited by 476
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
Brezinschek, H. P., Brezinschek, R. I., & Lipsky, P. E. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.190 · Cited by 419
Research works printed but not linked: 1
- Griffiths, A.D., Hoogenboom, H.R., 1993. Building an in vitro immune system: human antibodies from phage display libraries. In: Nottingham, C.M. (Ed.), Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Application in Man. Academic Titles, p. 45.
Cited by
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
“34 ) and use two different engineering approaches to inactivate endogenous mouse genes and to insert exogenous human immunoglobulin gene”
BackgroundKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
“Recently, fully human sequence antibodies isolated from mice carrying genetic modifications such that the murine immunoglobulin genes were disabled and replaced with functional human immunoglobulin loci have been approved for therapeutic use.(9,72) These antibodies undergo affinity maturation in vivo and therefore may…”
BackgroundChallita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
“The fully human monoclonal antibody (mAb) AGS-22M6 targeting the ECD of human nectin-4 was generated using the Xenomouse® platform developed by Amgen (formerly Abgenix, Thousand Oaks, CA) (14).”
MethodTraggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
“and (iii) immunization of transgenic mice carrying human immunoglobulin loci, followed by production of monoclonal antibodies using hybridoma technolog”
Metadata
- Authors
- Green, L. L.
- Corresponding author
- Green, Larry L
- Venue
- Journal of Immunological Methods
- Publisher
- Elsevier BV
- Published
- 1999-12
- Volume
- 231
- Issue
- 1-2
- Pages
- 11-23
- ISSN
- 0022-1759 (ISSN-L)
- OpenAlex
- W1992767687
- Cited by
- 229
- References
- 50
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 4 · 2021: 4 · 2020: 6 · 2019: 10 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 8 · 2014: 4 · 2013: 17 · 2012: 13
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Immunological Methods (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Health Sciences › Medicine › Surgery › Xenotransplantation and immune response
- Keywords
- humanized mice, monoclonal antibodies, therapeutic antibodies, immunogenicity, B cell development, secondary immune response, pharmacokinetics, antibody affinity
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Affinity, B-Lymphocytes, Genetic Engineering, Humans, Immunoglobulin G, Immunoglobulin M, Immunoglobulin Variable Region, Protein Engineering, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. https://app.cochat.ai/papers/10.1016/s0022-1759(99)00137-4
- The paper
- Green, L. L. (1999). Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. Journal of Immunological Methods. https://doi.org/10.1016/s0022-1759(99)00137-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.